Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics

American Journal of Physiology - Endocrinology and Metabolism

Volumn 302, Issue 1, 2012, Pages

  Doliba, Nicolai M ^a   Qin, Wei ^a   Najafi, Habiba ^a   Liu, Chengyang ^b   Buettger, Carol W ^a   Sotiris, Johanna ^b   Collins, Heather W ^a   Li, Changhong ^c   Stanley, Charles A ^c   Wilson, David F ^a   Grimsby, Joseph ^d   Sarabu, Ramakanth ^d   Naji, Ali ^b   Matschinsky, Franz M ^a  

^a Institute for Diabetes Obesity and Metabolism   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d Hoffman La Roche Department of Metabolic Diseases   (United States)

Author keywords

Glucokinase activators; Insulin secretion; Pancreatic islets; Type 2 diabetes

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM ION; EXENDIN 4; GLUCOKINASE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOENERGY; CALCIUM CELL LEVEL; CELL RESPIRATION; CONTROLLED STUDY; DIABETOGENESIS; ENZYME ACTIVATION; GLUCOSE OXIDATION; HUMAN; HUMAN TISSUE; INSULIN RELEASE; LANGERHANS CELL; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ADULT; ANIMALS; BENZENEACETAMIDES; CALCIUM SIGNALING; CELL RESPIRATION; DIABETES MELLITUS, TYPE 2; ENZYME ACTIVATORS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOKINASE; GLUCOSE; GLYCOLYSIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MALE; MICE; MIDDLE AGED; OXIDATIVE PHOSPHORYLATION; PEPTIDES; RATS; SPECIES SPECIFICITY; TISSUE CULTURE TECHNIQUES; VENOMS;

EID: 83455197122     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00218.2011     Document Type: Article

References (78)

1. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 414: 1-18, 2008.
2. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 8: 369-385, 2009.
3. Anello M, Lupi R, Spampinato D, Piro S, Masini M, Boggi U, Del Prato S, Rabuazzo AM, Purrello F, Marchetti P. Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. Diabetologia 48: 282-289, 2005.
4. Ashcroft FM, Harrison DE, Ashcroft SJ. Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells. Nature 312: 446-448, 1984.
5. Ashcroft FM, Harrison DE, Ashcroft SJ. A potassium channel modulated by glucose metabolism in rat pancreatic beta-cells. Adv Exp Med Biol 211: 53-62, 1986.
6. Ashcroft SJ, Weerasinghe LC, Bassett JM, Randle PJ. The pentose cycle and insulin release in mouse pancreatic islets. Biochem J 126: 525-532, 1972.
7. Baltrusch SW, Okar DA, Tiedge M, Lange AJ. Interaction of GK with the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (6PF2K/F26P2ase). In: Frontiers in Diabetes Glucokinase and Glycemic Disease: From Basic to Novel Therapeutics, edited by Matschinsky FM. Basel, Switzerland: Karger, 2004, p. 360-378.
8. Boden G, Chen X. Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. Diabetes 48: 577-583, 1999.
9. Bonadonna RC, Heise T, Arbet-Engels C, Kapitza C, Avogaro A, Grimsby J, Zhi J, Grippo JF, Balena R. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 95: 5028-5036, 2010.
10. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhausl W, Furnsinn C. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53: 1052-1059, 2004.
11. Campbell IW, Mariz S. Beta-cell preservation with thiazolidinediones. Diabetes Res Clin Pract 76: 163-176, 2007.
12. Danial NN, Gramm CF, Scorrano L, Zhang CY, Krauss S, Ranger AM, Datta SR, Greenberg ME, Licklider LJ, Lowell BB, Gygi SP, Korsmeyer SJ. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424: 952-956, 2003.
13. Danial NN, Walensky LD, Zhang CY, Choi CS, Fisher JK, Molina AJ, Datta SR, Pitter KL, Bird GH, Wikstrom JD, Deeney JT, Robertson K, Morash J, Kulkarni A, Neschen S, Kim S, Greenberg ME, Corkey BE, Shirihai OS, Shulman GI, Lowell BB, Korsmeyer SJ. Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat Med 14: 144-153, 2008.
14. Del Guerra S, Lupi R, Marselli L, Masini M, Bugliani M, Sbrana S, Torri S, Pollera M, Boggi U, Mosca F, Del Prato S, Marchetti P. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 54: 727-735, 2005.
15. Deng S, Vatamaniuk M, Huang X, Doliba N, Lian MM, Frank A, Velidedeoglu E, Desai NM, Koeberlein B, Wolf B, Barker CF, Naji A, Matschinsky FM, Markmann JF. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 53: 624-632, 2004.
16. Deng S, Vatamaniuk M, Lian MM, Doliba N, Wang J, Bell E, Wolf B, Raper S, Matschinsky FM, Markmann JF. Insulin gene transfer enhances the function of human islet grafts. Diabetologia 46: 386-393, 2003.
17. Doliba NM, Qin W, Vatamaniuk MZ, Buettger CW, Collins HW, Magnuson MA, Kaestner KH, Wilson DF, Carr RD, Matschinsky FM. Cholinergic regulation of fuel-induced hormone secretion and respiration of SUR1-/- mouse islets. Am J Physiol Endocrinol Metab 291: E525-E535, 2006.
18. Doliba NM, Qin W, Vatamaniuk MZ, Li C, Zelent D, Najafi H, Buettger CW, Collins HW, Carr RD, Magnuson MA, Matschinsky FM. Restitution of defective glucose-stimulated insulin release of sulfonylurea type 1 receptor knockout mice by acetylcholine. Am J Physiol Endocrinol Metab 286: E834-E843, 2004.
19. Doliba NM, Qin W, Vinogradov SA, Wilson DF, Matschinsky FM. Palmitic acid acutely inhibits acetylcholine- but not GLP-1-stimulated insulin secretion in mouse pancreatic islets. Am J Physiol Endocrinol Metab 299: E475-E485, 2010.
20. Doliba NM, Vatamaniuk MZ, Buettger CW, Qin W, Collins HW, Wehrli SL, Carr RD, Matschinsky FM. Differential effects of glucose and glyburide on energetics and Na levels of betaHC9 cells: nuclear magnetic resonance spectroscopy and respirometry studies. Diabetes 52: 394-402, 2003.
21. Doria A, Patti ME, Kahn CR. The emerging genetic architecture of type 2 diabetes. Cell Metab 8: 186-200, 2008.
22. Gao ZY, Li G, Najafi H, Wolf BA, Matschinsky FM. Glucose regulation of glutaminolysis and its role in insulin secretion. Diabetes 48: 1535-1542, 1999.
23. Ghosh A, Ronner P, Cheong E, Khalid P, Matschinsky FM. The role of ATP and free ADP in metabolic coupling during fuel-stimulated insulin release from islet beta-cells in the isolated perfused rat pancreas. J Biol Chem 266: 22887-22892, 1991.
24. Gilbert M, Jung SR, Reed BJ, Sweet IR. Islet oxygen consumption and insulin secretion tightly coupled to calcium derived from L-type calcium channels but not from the endoplasmic reticulum. J Biol Chem 283: 24334-24342, 2008.
25. Gloyn AL, Odili S, Buettger C, Njolstad PR, Shiota C, Magnuson MA, Matschinsky FM. A mathematical model predicts the threshold for glucose stimulated insulin release for GCK gene mutations that cause hyper- and hypoglycemia. In: Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics, edited by Matschinsky FM and Magnuson MA. New York: Karger, 2004, p. 92-109.
26. Grimsby J, Berthel SJ, Sarabu R. Glucokinase activators for the potential treatment of type 2 diabetes. Curr Top Med Chem 8: 1524-1532, 2008.
27. Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, Mahaney PE, Marcus L, Qi L, Spence CL, Tengi J, Magnuson MA, Chu CA, Dvorozniak MT, Matschinsky FM, Grippo JF. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301: 370-373, 2003.
28. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49: 1751-1760, 2000.
29. Henquin JC, Dufrane D, Nenquin M. Nutrient control of insulin secretion in isolated normal human islets. Diabetes 55: 3470-3477, 2006.
30. Jitrapakdee S, Wutthisathapornchai A, Wallace JC, MacDonald MJ. Regulation of insulin secretion: role of mitochondrial signalling. Diabetologia 53: 1019-1032, 2010.
31. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46: 3-19, 2003.
32. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427-2443, 2006.
33. Kahn SE, Zraika S, Utzschneider KM, Hull RL. The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 52: 1003-1012, 2009.
34. Kang G, Chepurny OG, Holz GG. cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells. J Physiol 536: 375-385, 2001.
35. Khan A, Ostenson CG, Berggren PO, Efendic S. Glucocorticoid increases glucose cycling and inhibits insulin release in pancreatic islets of ob/ob mice. Am J Physiol Endocrinol Metab 263: E663-E666, 1992.
36. Lamontagne J, Pepin E, Peyot ML, Joly E, Ruderman NB, Poitout V, Madiraju SR, Nolan CJ, Prentki M. Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic beta-cell at submaximal glucose concentrations. Endocrinology 150: 3465-3474, 2009.
37. Lebedev AY, Cheprakov AV, Sakadzi ́c S, Boas DA, Wilson DF, Vinogradov SA. Dendritic phosphorescent probes for oxygen imaging in biological systems. ACS Appl Mater Interfaces 1: 1292-1304, 2009.
38. Li C, Buettger C, Kwagh J, Matter A, Daikhin Y, Nissim IB, Collins HW, Yudkoff M, Stanley CA, Matschinsky FM. A signaling role of glutamine in insulin secretion. J Biol Chem 279: 13393-13401, 2004.
39. Li C, Chen P, Palladino A, Narayan S, Russell LK, Sayed S, Xiong G, Chen J, Stokes D, Butt YM, Jones PM, Collins HW, Cohen NA, Cohen AS, Nissim I, Smith TJ, Strauss AW, Matschinsky FM, Bennett MJ, Stanley CA. Mechanism of hyperinsulinism in short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency involves activation of glutamate dehydrogenase. J Biol Chem 285: 31806-31818, 2010.
40. Li C, Matter A, Kelly A, Petty TJ, Najafi H, MacMullen C, Daikhin Y, Nissim I, Lazarow A, Kwagh J, Collins HW, Hsu BY, Nissim I, Yudkoff M, Matschinsky FM, Stanley CA. Effects of a GTP-insensitive mutation of glutamate dehydrogenase on insulin secretion in transgenic mice. J Biol Chem 281: 15064-15072, 2006.
41. Li C, Najafi H, Daikhin Y, Nissim IB, Collins HW, Yudkoff M, Matschinsky FM, Stanley CA. Regulation of leucine-stimulated insulin secretion and glutamine metabolism in isolated rat islets. J Biol Chem 278: 2853-2858, 2003.
42. Li C, Nissim I, Chen P, Buettger C, Najafi H, Daikhin Y, Nissim I, Collins HW, Yudkoff M, Stanley CA, Matschinsky FM. Elimination of KATP channels in mouse islets results in elevated [U-13C]glucose metabolism, glutaminolysis, and pyruvate cycling but a decreased gammaaminobutyric acid shunt. J Biol Chem 283: 17238-17249, 2008.
43. Li CL, Nissim I, Chen P, Doliba N, Nissim I, Daikhin Y, Stokes D, Yudkoff M, Stanley CA, Matschinsky FM, Daikhin A. Islets of human type 2 diabetics have decreased GABA shunt and dysregulated glucose metabolism (Abstract). Diabetes 58, Suppl 1: A424, 2009.
44. Liang Y, Bai G, Doliba N, Buettger C, Wang L, Berner DK, Matschinsky FM. Glucose metabolism and insulin release in mouse beta HC9 cells, as model for wild-type pancreatic β-cells. Am J Physiol Endocrinol Metab 270: E846-E857, 1996.
45. Liu S, Okada T, Assmann A, Soto J, Liew CW, Bugger H, Shirihai OS, Abel ED, Kulkarni RN. Insulin signaling regulates mitochondrial function in pancreatic beta-cells. PLoS One 4: e7983, 2009.
46. Lu H, Koshkin V, Allister EM, Gyulkhandanyan AV, Wheeler MB. Molecular and metabolic evidence for mitochondrial defects associated with beta-cell dysfunction in a mouse model of type 2 diabetes. Diabetes 59: 448-459, 2010.
47. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund G, Altshuler D, Nilsson P, Groop L. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 359: 2220-2232, 2008.
48. MacDonald MJ, Longacre MJ, Langberg EC, Tibell A, Kendrick MA, Fukao T, Ostenson CG. Decreased levels of metabolic enzymes in pancreatic islets of patients with type 2 diabetes. Diabetologia 52: 1087-1091, 2009.
49. MacDonald MJ, Longacre MJ, Stoker SW, Kendrick M, Thonpho A, Brown LJ, Hasan NM, Jitrapakdee S, Fukao T, Hanson MS, Fernandez LA, Odorico J. Differences between human and rodent pancreatic islets: low pyruvate carboxylase, atp citrate lyase, and pyruvate carboxylation and high glucose-stimulated acetoacetate in human pancreatic islets. J Biol Chem 286: 18383-18396, 2011.
50. Madison LL, Mebane D, Unger RH, Lochner A. The hypoglycemic action of ketones. II. Evidence for a stimulatory feedback of ketones on the pancreatic beta cells. J Clin Invest 43: 408-415, 1964.
51. Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8: 399-416, 2009.
52. Matschinsky FM. Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 45: 223-241, 1996.
53. Matschinsky FM, Ellerman JE, Landgraf, krzanowski J, Kotler-Brajtburg J, Fertel R. Quantitative histochemistry of glucose metabolism in the islets of Langerhans. Curr Probl Clin Biochem 3: 143-182, 1971.
54. Matschinsky FM, Zelent B, Doliba NM, Kaestner KH, Vanderkooi JM, Grimsby J, Berthel SJ, Sarabu R. Research and development of glucokinase activators. In: Diabetes - Perspectives in Drug Therapy, edited by Schwanstecher M. New York: Springer, 2011, p. 357-401.
55. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 15: 297-303, 1998.
56. McCarthy MI, Froguel P. Genetic approaches to the molecular understanding of type 2 diabetes. Am J Physiol Endocrinol Metab 283: E217-E225, 2002.
57. Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, Manning AK, Florez JC, Wilson PW, D'Agostino RB Sr, Cupples LA. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 359: 2208-2219, 2008.
58. Miwa IT, Yoshie S. Glucokinase in beta-cell insulin-secretory granules. In: Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics, edited by Matschinsky FM. New York: Karger, 2004, p. 350-359.
59. Mulder H, Ling C. Mitochondrial dysfunction in pancreatic beta-cells in Type 2 diabetes. Mol Cell Endocrinol 297: 34-40, 2009.
60. Newgard CB, Matschinsky FM. Substrate control of insulin release. In: Handbook of Physiology, edited by Jefferson L. Oxford, CA: Oxford Univ. Press, 2001, p. 125-151.
61. Nolan CJ, Madiraju MS, Delghingaro-Augusto V, Peyot ML, Prentki M. Fatty acid signaling in the beta-cell and insulin secretion. Diabetes 55, Suppl 2: S16-S23, 2006.
62. Nolte MS. Pancreatic Hormones and Antidiabetic Drugs. New York: McGraw Hill, 2007, p. 697-698.
63. O'Doherty RM, Lehman DL, Telemaque-Potts S, Newgard CB. Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes 48: 2022-2027, 1999.
64. Ohyama S, Takano H, Iino T, Nishimura T, Zhou YP, Langdon RB, Zhang BB, Eiki J. A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat. Eur J Pharmacol 640: 250-256, 2010.
65. Owen OE, Reichard GA Jr, Markus H, Boden G, Mozzoli MA, Shuman CR. Rapid intravenous sodium acetoacetate infusion in man. Metabolic and kinetic responses. J Clin Invest 52: 2606-2616, 1973.
66. Pearson ER. Translating TCF7L2: from gene to function. Diabetologia 52: 1227-1230, 2009.
67. Prentki M, Matschinsky FM. Ca2, cAMP, and phospholipid-derived messengers in coupling mechanisms of insulin secretion. Physiol Rev 67: 1185-1248, 1987.
68. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988.
69. Ridderstrale M, Groop L. Genetic dissection of type 2 diabetes. Mol Cell Endocrinol 297: 10-17, 2009.
70. Riedel AA, Heien H, Wogen J, Plauschinat CA. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 27: 1102-1110, 2007.
71. Sagen JV, Odili S, Bjørkhaug L, Zelent D, Buettger C, Kwagh J, Stanley C, Dahl-Jørgensen K, de Beaufort C, Bell GI, Han Y, Grimsby J, Taub R, Molven A, Søvik O, Njølstad PR, Matschinsky FM. From clinicogenetic studies of maturity-onset diabetes of the young to unraveling complex mechanisms of glucokinase regulation. Diabetes 55: 1713-1722, 2006.
72. Shiota C, Larsson O, Shelton KD, Shiota M, Efanov AM, Hoy M, Lindner J, Kooptiwut S, Juntti-Berggren L, Gromada J, Berggren PO, Magnuson MA. Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose. J Biol Chem 277: 37176-37183, 2002.
73. Smith DO, LeRoith D. Insulin resistance syndrome, pre-diabetes, and the prevention of type 2 diabetes mellitus. Clin Cornerstone 6: 7-6, 2004.
74. Sorenson RL, Stout LE, Brelje TC, Jetton TL, Matschinsky FM. Immunohistochemical evidence for the presence of glucokinase in the gonadotropes and thyrotropes of the anterior pituitary gland of rat and monkey. J Histochem Cytochem 55: 555-566, 2007.
75. Sweet IR, Li G, Najafi H, Berner D, Matschinsky FM. Effect of a glucokinase inhibitor on energy production and insulin release in pancreatic islets. Am J Physiol Endocrinol Metab 271: E606-E625, 1996.
76. Takamoto I, Terauchi Y, Kubota N, Ohsugi M, Ueki K, Kadowaki T. Crucial role of insulin receptor substrate-2 in compensatory beta-cell hyperplasia in response to high fat diet-induced insulin resistance. Diabetes Obes Metab 10, Suppl 4: 147-156, 2008.
77. Wang X, Zhou L, Shao L, Qian L, Fu X, Li G, Luo T, Gu Y, Li F, Li J, Zheng S, Luo M. Troglitazone acutely activates AMP-activated protein kinase and inhibits insulin secretion from beta cells. Life Sci 81: 160-165, 2007.
78. Zawalich WS, Dye ES, Matschinsky FM. Metabolism and insulinreleasing capabilities of glucosamine and N-acetylglucosamine in isolated rat islets. Biochem J 180: 145-152, 1979.